Display options
Cite
Veschi V, Petroni M, Cardinali B, et al. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells. PLoS One. 2012;7(11):e49139doi: 10.1371/journal.pone.0049139.
Veschi, V., Petroni, M., Cardinali, B., Dominici, C., Screpanti, I., Frati, L., Bartolazzi, A., Gulino, A., & Giannini, G. (2012). Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells. PloS one, 7(11), e49139. https://doi.org/10.1371/journal.pone.0049139
Veschi, Veronica, et al. "Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells." PloS one vol. 7,11 (2012): e49139. doi: https://doi.org/10.1371/journal.pone.0049139
Veschi V, Petroni M, Cardinali B, Dominici C, Screpanti I, Frati L, Bartolazzi A, Gulino A, Giannini G. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells. PLoS One. 2012;7(11):e49139. doi: 10.1371/journal.pone.0049139. Epub 2012 Nov 09. PMID: 23152863; PMCID: PMC3494673.
Copy Download .nbib Format: NLM
Share it on

PLoS One. 2012;7(11):e49139. doi: 10.1371/journal.pone.0049139. Epub 2012 Nov 09.

Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.

PloS one

Veronica Veschi, Marialaura Petroni, Beatrice Cardinali, Carlo Dominici, Isabella Screpanti, Luigi Frati, Armando Bartolazzi, Alberto Gulino, Giuseppe Giannini

Affiliations

  1. Department of Experimental Medicine, Sapienza University, Rome, Italy.

PMID: 23152863 PMCID: PMC3494673 DOI: 10.1371/journal.pone.0049139

Abstract

MYCN amplification occurs in about 20-25% of human neuroblastomas and characterizes the majority of the high-risk cases, which display less than 50% prolonged survival rate despite intense multimodal treatment. Somehow paradoxically, MYCN also sensitizes neuroblastoma cells to apoptosis, understanding the molecular mechanisms of which might be relevant for the therapy of MYCN amplified neuroblastoma. We recently reported that the apoptosis-sensitive phenotype induced by MYCN is linked to stabilization of p53 and its proapoptotic kinase HIPK2. In MYCN primed neuroblastoma cells, further activation of both HIPK2 and p53 by Nutlin-3 leads to massive apoptosis in vitro and to tumor shrinkage and impairment of metastasis in xenograft models. Here we report that Galectin-3 impairs MYCN-primed and HIPK2-p53-dependent apoptosis in neuroblastoma cells. Galectin-3 is broadly expressed in human neuroblastoma cell lines and tumors and is repressed by MYCN to induce the apoptosis-sensitive phenotype. Despite its reduced levels, Galectin-3 can still exert residual antiapoptotic effects in MYCN amplified neuroblastoma cells, possibly due to its specific subcellular localization. Importantly, Nutlin-3 represses Galectin-3 expression, and this is required for its potent cell killing effect on MYCN amplified cell lines. Our data further characterize the apoptosis-sensitive phenotype induced by MYCN, expand our understanding of the activity of MDM2-p53 antagonists and highlight Galectin-3 as a potential biomarker for the tailored p53 reactivation therapy in patients with high-risk neuroblastomas.

References

  1. Neoplasia. 2008 Nov;10(11):1268-74 - PubMed
  2. Cancer Lett. 2003 May 30;195(1):111-9 - PubMed
  3. Drug Resist Updat. 2007 Jun;10(3):101-8 - PubMed
  4. Oncogene. 1996 Aug 15;13(4):803-12 - PubMed
  5. Lancet. 2001 May 26;357(9269):1644-50 - PubMed
  6. Cancer Res. 2010 Feb 15;70(4):1377-88 - PubMed
  7. Lancet Oncol. 2008 Jun;9(6):543-9 - PubMed
  8. Cancer Lett. 2005 Oct 18;228(1-2):97-104 - PubMed
  9. Nat Rev Cancer. 2008 Dec;8(12):976-90 - PubMed
  10. Neoplasia. 2008 Aug;10(8):773-81 - PubMed
  11. J Clin Oncol. 2009 Mar 1;27(7):1014-9 - PubMed
  12. Nature. 2007 Feb 8;445(7128):661-5 - PubMed
  13. Oncogene. 2004 Sep 30;23(45):7527-36 - PubMed
  14. J Clin Oncol. 2009 Jan 10;27(2):289-97 - PubMed
  15. Oncogene. 1999 Feb 18;18(7):1479-86 - PubMed
  16. Clin Cancer Res. 2002 Aug;8(8):2570-5 - PubMed
  17. J Natl Cancer Inst. 2003 Sep 17;95(18):1394-403 - PubMed
  18. Int J Oncol. 2001 Apr;18(4):787-92 - PubMed
  19. Ann N Y Acad Sci. 2004 Dec;1028:122-32 - PubMed
  20. Mol Cancer Res. 2011 Jan;9(1):67-77 - PubMed
  21. Nat Rev Cancer. 2009 Oct;9(10):714-23 - PubMed
  22. PLoS One. 2011;6(6):e20665 - PubMed
  23. J Pathol. 2009 May;218(1):66-75 - PubMed
  24. Mol Cell Biol. 2004 May;24(10):4395-406 - PubMed
  25. Cell Death Differ. 2009 Dec;16(12):1563-72 - PubMed
  26. Nat Cell Biol. 2002 Jan;4(1):11-9 - PubMed
  27. Cancer Lett. 2003 Jul 18;197(1-2):93-8 - PubMed
  28. Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):731-6 - PubMed
  29. Int J Clin Oncol. 2011 Aug;16(4):352-8 - PubMed
  30. Int J Cancer. 2012 Aug 15;131(4):E337-47 - PubMed
  31. J Natl Cancer Inst. 2009 Nov 18;101(22):1562-74 - PubMed
  32. Prog Clin Biol Res. 1988;271:291-306 - PubMed
  33. Cell Cycle. 2007 Nov 1;6(21):2685-96 - PubMed
  34. Oncogene. 1995 Dec 21;11(12):2599-607 - PubMed
  35. Oncogene. 2002 Sep 5;21(39):6132-7 - PubMed
  36. Thyroid. 2009 Nov;19(11):1167-214 - PubMed
  37. Tumour Biol. 2010 Aug;31(4):277-85 - PubMed
  38. Cancer Res. 1997 Dec 1;57(23):5272-6 - PubMed
  39. Science. 1997 Feb 21;275(5303):1129-32 - PubMed
  40. Clin Exp Metastasis. 1989 Mar-Apr;7(2):201-11 - PubMed
  41. Prostate. 2000 Jul 1;44(2):118-23 - PubMed
  42. Anticancer Res. 2005 Jul-Aug;25(4):3117-21 - PubMed
  43. Cancer Cell. 2004 Dec;6(6):625-30 - PubMed
  44. Int J Oncol. 1998 Jun;12(6):1287-90 - PubMed
  45. EMBO J. 1997 Jun 2;16(11):2985-95 - PubMed
  46. Cancer Res. 2006 Mar 15;66(6):3114-9 - PubMed
  47. Br J Cancer. 2000 Dec;83(11):1503-9 - PubMed
  48. Int J Oncol. 2007 May;30(5):1189-96 - PubMed
  49. Cancer Res. 1998 Dec 1;58(23):5396-405 - PubMed
  50. Mol Cell Biol. 2006 Jun;26(12):4746-57 - PubMed
  51. Cancer Res. 2006 Mar 1;66(5):2826-33 - PubMed
  52. Biochim Biophys Acta. 2010 Feb;1800(2):181-9 - PubMed
  53. J Biol Chem. 2002 May 3;277(18):15819-27 - PubMed
  54. Cell Tissue Res. 2006 Jan;323(1):81-90 - PubMed
  55. Nat Rev Clin Oncol. 2011 Jan;8(1):25-37 - PubMed
  56. Oncogene. 1995 Nov 16;11(10):2165-74 - PubMed
  57. Cancer Res. 1999 May 15;59(10):2484-92 - PubMed
  58. Nature. 2007 Feb 8;445(7128):656-60 - PubMed
  59. Cell. 2006 Dec 29;127(7):1323-34 - PubMed
  60. Clin Cancer Res. 2010 Feb 15;16(4):1108-18 - PubMed
  61. Oncogene. 2012 Feb 9;31(6):752-63 - PubMed
  62. Cancer Res. 2005 Sep 15;65(18):8308-16 - PubMed
  63. Cancer Res. 2009 Aug 1;69(15):6241-8 - PubMed
  64. Biochim Biophys Acta. 2006 Apr;1760(4):616-35 - PubMed
  65. Cell Cycle. 2006 Nov;5(22):2639-47 - PubMed
  66. J Clin Oncol. 2009 Jan 20;27(3):365-70 - PubMed

Substances

MeSH terms

Publication Types

Grant support